Federal Register / Vol. 72, No. 102 / Tuesday, May 29, 2007 / Notices 29521 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact AnnMarie 

Williams, Conference Management 

Staff, at 240–276–8932, at least 7 days 

in advance of the meeting. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: May 22, 2007. 

Randall W. Lutter, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E7–10267 Filed 5–25–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center on Minority Health and 

Health Disparities; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Minority Health and Health Disparities 

Special Emphasis Panel; LRP for Health 

Disparities and Clinical Research-Panel-D. 

Date: June 15, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6707 

Democracy Blvd., Suite 800, Bethesda, MD 

20892, (Virtual Meeting). 

Contact Person: Lorrita Watson, PhD, 

National Center on Minority Health, and 

Health Disparities, National Institutes of 

Health, 6707 Democracy Blvd, Suite 800, 

Bethesda, MD 20892–5465, (301) 402–1366, 

watsonl@ncmhd.nih.gov. 

Dated: May 21, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2619 Filed 5–25–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Rehabilitation for Methamphetamine 

Induced Impulsivity. 

Date: June 5, 2007. 

Time: 1:30 p.m. to 2:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Lyle Furr, Contract Review 

Specialist, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, (301) 

435–1439, lf33c.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: May 21, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2611 Filed 5–25–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, 

Exploratory/Development Centers. 

Date: June 27–28, 2007. 

Time: 8:30 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate Hotel, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Mark Swieter, PhD, Chief, 

Training and Special Projects Review Branch, 

Office of Extramural Affairs, National 

Institute on Drug Abuse, NIH, DHHS, 6101 

Executive Boulevard, Suite 220, Bethesda, 

MD 20892–8401, (301) 435–1389, 

ms80x@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, Gene by 

Environment Initiative. 

Date: July 3, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Fairmont Washington, DC, 2401 

M Street NW., Washington, DC 20037. 

Contact Person: Rita Liu, PhD, Associate 

Director, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 212, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, 

301.435.1388, rliu@nida.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, 

Mechanisms of Drug Abuse Interactions with 

HIV Neuropathogenesis. 

Date: July 12, 2007. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Omni Shoreham Hotel, 2500 Calvert 

Street, NW., Washington, DC 20008. 

Contact Person: Nadine Rogers, Health 

Scientist Administrator, Office of Extramural 

Affairs, National Institute on Drug Abuse, 

NIH, DHHS, Room 220, MSC 8401, 6101 

Executive Boulevard, Bethesda, MD 20892–

8401, 301–402–2105, rogersn2@nida.nih.gov. 


sroberts on PROD1PC70 with NOTICES